Title: Effect of montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Version: 2 Date: 23 Jan 2025
Reviewer's report:
BMC Gastroenterology
Effect of Montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Although various drugs have been developed for ulcerative colitis, not all cases are able to induce
and maintain remission. In particular, ulcerative colitis is a disease that relapses repeatedly,
so maintenance therapy is important. This study is significant in considering new maintenance
therapies. However, as the author also points out in the limitations, there is a major problem.
There were significant differences in fecal calprotectin, serum CRP, and ESR between the two
groups before intervention. If there is a significant difference in the baseline between the two
groups, would there be no need to change the study design, such as reporting the effects in one
group?
Please provide a table showing the treatment at the time of induction of remission.
Please describe the concomitant use of maintenance drugs and the side effects of Montelukas.
Title: Effect of montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Version: 2 Date: 23 Jan 2025
Reviewer's report:
BMC Gastroenterology
Effect of Montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Although various drugs have been developed for ulcerative colitis, not all cases are able to induce
and maintain remission. In particular, ulcerative colitis is a disease that relapses repeatedly,
so maintenance therapy is important. This study is significant in considering new maintenance
therapies. However, as the author also points out in the limitations, there is a major problem.
There were significant differences in fecal calprotectin, serum CRP, and ESR between the two
groups before intervention. If there is a significant difference in the baseline between the two
groups, would there be no need to change the study design, such as reporting the effects in one
group?
Please provide a table showing the treatment at the time of induction of remission.
Please describe the concomitant use of maintenance drugs and the side effects of Montelukas.
Please review this paper.
user
Title: Effect of montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Version: 2 Date: 23 Jan 2025
Reviewer's report:
BMC Gastroenterology
Effect of Montelukast on remission maintenance in patients with ulcerative colitis: A
Randomized, double-blind controlled clinical trial
Although various drugs have been developed for ulcerative colitis, not all cases are able to induce
and maintain remission. In particular, ulcerative colitis is a disease that relapses repeatedly,
so maintenance therapy is important. This study is significant in considering new maintenance
therapies. However, as the author also points out in the limitations, there is a major problem.
There were significant differences in fecal calprotectin, serum CRP, and ESR between the two
groups before intervention. If there is a significant difference in the baseline between the two
groups, would there be no need to change the study design, such as reporting the effects in one
group?
Please provide a table showing the treatment at the time of induction of remission.
Please describe the concomitant use of maintenance drugs and the side effects of Montelukas.
assistant